Annual report [Section 13 and 15(d), not S-K Item 405]

Royalty and Commercial Payment Purchase Agreements - Fully Recovered - Viracta (Details)

v3.25.1
Royalty and Commercial Payment Purchase Agreements - Fully Recovered - Viracta (Details)
$ in Thousands
 12 Months Ended
May 30, 2024
USD ($)
Apr. 23, 2024
USD ($)
Oct. 30, 2023
USD ($)
Mar. 22, 2021
USD ($)
item
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Agreements            
Payments of consideration under RPAs, AAAs and CPPAs         $ 53,000 $ 14,650
Long-term royalty and commercial payment receivables under the cost recovery method         55,936 57,952
Acquisition of royalty and commercial payment receivables         45,000  
Reduction in long-term royalty receivable balance due to receipt of payment         18,938  
Change in fair value of embedded derivative related to RPA         8,100  
Trade and other receivables, net         1,839 1,004
Income from purchased receivables under cost recovery method         3,201  
Viracta            
Agreements            
Reduction in long-term royalty receivable balance due to receipt of payment         8,500  
Income from purchased receivables under cost recovery method         3,201  
Viracta | Royalty Purchase Agreement            
Agreements            
Number of drug candidates | item       2    
Payments of consideration under RPAs, AAAs and CPPAs       $ 13,500    
Maximum amount of potential milestones, potential royalties on sales and other payments receivable       54,000    
Amount of maximum consideration retained       5,000    
Maximum amount of potential regulatory and commercial milestones receivable       57,000    
Long-term royalty and commercial payment receivables under the cost recovery method       $ 13,500 0  
Amount of milestone payments earned under agreement   $ 9,000 $ 5,000      
Reduction in long-term royalty receivable balance due to receipt of payment   $ 8,500 $ 5,000      
Sale of priority review voucher to undisclosed buyer $ 108,000          
Allowance for credit losses           0
Trade and other receivables, net         1,300 0
Income from purchased receivables under cost recovery method         3,200 $ 0
Viracta | Royalty Purchase Agreement | OJEMDA            
Agreements            
Income from purchased receivables under cost recovery method         500  
Viracta | Royalty Purchase Agreement | Priority review voucher.            
Agreements            
Payment received related to sale $ 8,100          
Change in fair value of embedded derivative related to RPA         $ 8,100